Product Description
Ketamine is used by medical practitioners and veterinarians as an anaesthetic. It's sometimes used illegally by people to get high.
Mechanisms of Action: NMDA Antagonist, Excitatory Amino Acid Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: Eastern America
Company Founding Year: 1886
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, Spain, United States
Active Clinical Trial Count: 19
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Chronic Pain|Colorectal Cancer|Depressive Disorder, Major|Digestive System Cancer|Gastrointestinal Cancer|Headache Disorders|Intestinal Diseases|Liver Cancer|Migraine Disorders|Mouth Cancer|Mucositis|Oropharyngeal Cancer|Skin Cancer
Phase 2: Acute Pain|Depressive Disorder|Depressive Disorder, Treatment-Resistant|Healthy Volunteers|Methamphetamine Dependence|Stress Disorders, Post-Traumatic|Suicidality
Phase 1: Bipolar Disorder|Pneumothorax
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07307768 |
KETAEEG | P1 |
Not yet recruiting |
Depressive Disorder, Treatment-Resistant |
2027-12-01 |
50% |
2025-12-30 |
Primary Endpoints|Treatments |
NCT07040163 |
NCT07040163 | P1 |
Active, not recruiting |
Pneumothorax |
2026-02-13 |
2026-02-24 |
||
CTR20240561 |
CTR20240561 | P1 |
Completed |
Depressive Disorder |
2024-08-21 |
2025-07-27 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06816433 |
S-21-02 (SLS-002) | P2 |
Not yet recruiting |
Stress Disorders, Post-Traumatic |
2026-03-01 |
2% |
2025-02-14 |
Primary Endpoints |
NCT06538285 |
KARE | P2 |
Recruiting |
Methamphetamine Dependence |
2026-03-01 |
2025-03-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2023-504023-63-00 |
PDC 01-0202 | P2 |
Recruiting |
Acute Pain |
2024-12-31 |
16% |
2025-05-02 |
Treatments |
NCT04669665 |
SLS-002-201 | P2 |
Completed |
Depressive Disorder, Major|Suicidality |
2023-06-17 |
69% |
2023-09-29 |
|
NCT05306899 |
KetHead | P3 |
Recruiting |
Migraine Disorders|Chronic Pain|Headache Disorders |
2026-02-01 |
21% |
2025-11-18 |
Primary Endpoints |
ACTRN12619000108112 |
ACTRN12619000108112 | P3 |
Not yet recruiting |
Intestinal Diseases|Gastrointestinal Cancer|Mouth Cancer|Digestive System Cancer|Skin Cancer|Colorectal Cancer|Mucositis|Oropharyngeal Cancer|Liver Cancer |
2022-02-11 |
2026-02-15 |
Treatments |
|
2019-003109-92 |
KARMA-Dep (2) | P3 |
Active, not recruiting |
Depressive Disorder, Major |
2022-12-20 |
2022-03-13 |
Treatments |
|
2020-002905-24 |
Ketamine Trial for Acute suicidality (KETA) | P2 |
Active, not recruiting |
Suicidality |
2024-06-08 |
2022-03-13 |
Treatments |
|
2021-003258-21 |
2021-003258-21 | P2 |
Active, not recruiting |
Healthy Volunteers |
2023-05-19 |
2022-03-13 |
Treatments |
|
2021-004927-34 |
2021-004927-34 | P2 |
Completed |
Depressive Disorder, Treatment-Resistant |
2023-05-10 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20242441 |
CTR20242441 | P1 |
Completed |
Depressive Disorder, Treatment-Resistant |
2024-10-29 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20232056 |
CTR20232056 | P1 |
Completed |
Suicidality|Depressive Disorder |
2023-10-17 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ACTRN12625000942459 |
ACTRN12625000942459 | P1 |
Recruiting |
Bipolar Disorder |
None |
2026-02-15 |
Treatments |
|
ACTRN12623000061639 |
PSYCH007 | P2 |
Not yet recruiting |
Stress Disorders, Post-Traumatic |
None |
2026-02-15 |
Treatments |
|
CTR20251359 |
CTR20251359 | P2 |
Recruiting |
Suicidality|Depressive Disorder |
None |
2025-06-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20250133 |
CTR20250133 | P2 |
Recruiting |
Depressive Disorder |
None |
2025-07-19 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/03/2026 |
News Article |
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market |
|
02/05/2026 |
News Article |
Serenity Mental Health Centers Offers TMS Treatment in Nocatee |
|
02/05/2026 |
News Article |
Serenity Mental Health Centers Offers TMS Therapy in Las Vegas |
|
02/04/2026 |
News Article |
The Inner Circle acknowledges Jessica L. Ables as a Pinnacle Professional Member |